OpGen Inc (OPGN)

[chillswills37]

USPTO URL OpGen patent 10,876,162 Key in lock to treasure box. Granted 12.29.2020. Ares Genetics a tantalzing plum.

1) OPGN PR 12.01.2020 "Dr. Andreas Posch, former CEO Ares Genetics, added, “I am particularly excited about our collaboration with Sandoz (sub of Novartis [NVS]) on optimal antibiotic drug positioning based on molecular testing as well as our joint work with Johns Hopkins demonstrating feasibility of accurate AST prediction using long-read sequencing technology as this technology could potentially allow for rapid predictive AST directly from native patient samples.”

www (.) patft (.) uspto (.) gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=1&f=G&l=50&d=PTXT&S1=(20201229.PD.+AND+opgen)&OS=ISD/12/29/2020+AND+opgen&RS=(ISD/20201229+AND+opgen

United States Patent 10,876,162
Walker, et al. December 29, 2020
Methods of detecting multi-drug resistant organisms
Abstract

The present invention provide methods using genes associated with multi-drug resistance for rapidly detecting a patient colonized or infected with an multi-drug resistant organism and administrating the appropriate precautions and/or treatment.

Inventors: Walker; George Terrance (Chevy Chase, MD), Rockweiler; Tony (Arlington, VA), Saeed; Alex(Germantown, MD), Sapiro; Vadim (North Potomac, MD), Kersey; Rossio (Germantown, MD)

Applicant:

Name City State Country Type

OpGen, Inc. Gaithersburg MD US

Assignee: OPGEN, INC. (Gaithersburg, MD)

Family ID: 1000005272681

Appl. No.: 16/056,037

Filed: August 6, 2018

Prior Publication Data

Document Identifier Publication Date